Zentalis Pharmaceuticals, Inc.
ZNTL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $26,865 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $26,865 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $22,950 | $27,610 | $27,247 | $32,973 |
| G&A Expenses | $10,784 | $7,296 | $10,580 | $40,005 |
| SG&A Expenses | $10,784 | $7,296 | $10,580 | $40,005 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1,152 | $7,796 | $3,736 |
| Operating Expenses | $33,734 | $36,058 | $45,623 | $76,714 |
| Operating Income | -$33,734 | -$36,058 | -$45,623 | -$49,849 |
| % Margin | – | – | – | -185.6% |
| Other Income/Exp. Net | $7,043 | $9,184 | -$2,656 | $2,172 |
| Pre-Tax Income | -$26,691 | -$26,874 | -$48,279 | -$47,677 |
| Tax Expense | $0 | $0 | $0 | -$205 |
| Net Income | -$26,691 | -$26,874 | -$48,279 | -$47,472 |
| % Margin | – | – | – | -176.7% |
| EPS | -0.37 | -0.37 | -0.67 | -0.67 |
| % Growth | 0% | 44.8% | 0% | – |
| EPS Diluted | -0.37 | -0.37 | -0.67 | -0.67 |
| Weighted Avg Shares Out | 72,139 | 71,992 | 71,678 | 71,238 |
| Weighted Avg Shares Out Dil | 72,139 | 71,992 | 71,678 | 71,238 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $160 | $160 | $262 | $317 |
| EBITDA | -$26,531 | -$34,746 | -$37,565 | -$45,796 |
| % Margin | – | – | – | -170.5% |